Travere Therapeutics - TVTX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $15.58
  • Forecasted Upside: 130.52%
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$6.76
▲ +0.6 (9.74%)

This chart shows the closing price for TVTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Travere Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TVTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TVTX

Analyst Price Target is $15.58
▲ +130.52% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Travere Therapeutics in the last 3 months. The average price target is $15.58, with a high forecast of $27.00 and a low forecast of $9.00. The average price target represents a 130.52% upside from the last price of $6.76.

This chart shows the closing price for TVTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 investment analysts is to moderate buy stock in Travere Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/5/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/5/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
6/3/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/1/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
11/30/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/28/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
4/28/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/28/2024

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$19.00Low
5/7/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$15.00 ➝ $18.00Low
4/24/2024HC WainwrightBoost TargetBuy ➝ Buy$17.00 ➝ $19.00Low
4/17/2024WedbushReiterated RatingOutperform ➝ Outperform$13.00N/A
3/27/2024GuggenheimReiterated RatingBuy ➝ NeutralLow
3/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00Low
2/16/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$8.00 ➝ $9.00Low
2/16/2024WedbushReiterated RatingOutperform ➝ Outperform$13.00Low
1/18/2024Piper SandlerBoost TargetNeutral ➝ Neutral$10.00 ➝ $11.00Low
12/18/2023Stifel NicolausBoost TargetHold ➝ Hold$8.00 ➝ $10.00Low
12/15/2023HC WainwrightBoost TargetBuy ➝ Buy$18.00 ➝ $20.00Low
12/5/2023HC WainwrightReiterated RatingBuy ➝ Buy$18.00Low
12/5/2023CitigroupUpgradeNeutral ➝ Buy$7.00 ➝ $10.00Low
11/20/2023CitigroupInitiated CoverageNeutral$7.00Low
10/25/2023Piper SandlerLower TargetNeutral ➝ Neutral$19.00 ➝ $10.00Low
9/29/2023WedbushReiterated RatingOutperform ➝ Outperform$12.00Low
9/22/2023Evercore ISILower Target$30.00 ➝ $14.00Low
9/22/2023HC WainwrightLower TargetBuy ➝ Buy$32.00 ➝ $18.00Low
9/22/2023GuggenheimLower TargetBuy ➝ Buy$25.00 ➝ $18.00Low
9/22/2023Bank of AmericaLower TargetBuy ➝ Buy$41.00 ➝ $27.00Low
9/22/2023BarclaysLower TargetOverweight ➝ Overweight$31.00 ➝ $12.00Low
9/22/2023Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$24.00 ➝ $8.00Low
9/21/2023William BlairDowngradeOutperform ➝ Market PerformLow
9/19/2023Evercore ISIReiterated RatingOutperform ➝ Outperform$30.00Low
9/6/2023Evercore ISIInitiated CoverageOutperform ➝ Outperform$30.00Low
8/18/2023Piper SandlerLower TargetNeutral ➝ Neutral$22.00 ➝ $19.00Low
8/7/2023HC WainwrightLower TargetBuy ➝ Buy$35.00 ➝ $32.00Low
7/21/2023JPMorgan Chase & Co.Initiated CoverageOverweight$26.00Low
7/18/2023Canaccord Genuity GroupLower TargetBuy$37.00 ➝ $35.00Low
6/1/2023HC WainwrightBoost Target$22.00 ➝ $35.00Low
5/22/2023TD CowenInitiated CoverageOutperform$30.00Low
5/5/2023Bryan, Garnier & CoUpgradeSell ➝ NeutralLow
5/2/2023Evercore ISILower Target$36.00 ➝ $26.00Low
5/2/2023HC WainwrightLower Target$40.00 ➝ $22.00Low
5/2/2023Bank of AmericaLower Target$52.00 ➝ $39.00Low
5/2/2023GuggenheimLower Target$40.00 ➝ $23.00Low
4/17/2023WedbushLower TargetOutperform$30.00 ➝ $29.00Low
4/10/2023GuggenheimBoost Target$37.00 ➝ $40.00Low
3/13/2023Piper SandlerLower Target$44.00 ➝ $41.00Low
2/28/2023GuggenheimInitiated CoverageBuy$37.00Low
2/28/2023Canaccord Genuity GroupLower TargetBuy$44.00 ➝ $42.00Low
2/22/2023Canaccord Genuity GroupBoost TargetBuy$40.00 ➝ $44.00Low
2/21/2023Evercore ISIBoost Target$30.00 ➝ $36.00Low
2/21/2023Piper SandlerBoost TargetOverweight$42.00 ➝ $46.00Low
2/21/2023HC WainwrightBoost TargetBuy$36.00 ➝ $40.00Low
2/21/2023BarclaysLower TargetOverweight$37.00 ➝ $31.00Low
2/21/2023WedbushUpgradeNeutral ➝ Outperform$30.00Low
2/17/2023HC WainwrightReiterated RatingBuy$36.00N/A
1/30/2023Canaccord Genuity GroupBoost TargetBuy$33.00 ➝ $40.00Low
1/10/2023Piper SandlerBoost TargetOverweight$38.00 ➝ $42.00Low
12/13/2022Stifel NicolausInitiated CoverageHold$22.00Low
12/5/2022Wells Fargo & CompanyInitiated CoverageOverweight$28.00Low
10/20/2022Evercore ISILower Target$30.00Low
10/20/2022SVB LeerinkLower TargetOutperform$45.00 ➝ $38.00Low
10/14/2022HC WainwrightLower TargetBuy$42.00 ➝ $36.00Low
10/13/2022Piper SandlerLower TargetOverweight$39.00 ➝ $38.00Low
9/21/2022Bryan, Garnier & CoInitiated CoverageSell$17.00Low
8/15/2022Piper SandlerLower Target$41.00 ➝ $39.00Low
8/9/2022Evercore ISILower Target$35.00Low
8/9/2022BarclaysLower Target$37.00Low
8/8/2022HC WainwrightLower TargetBuy$46.00 ➝ $42.00Low
8/5/2022SVB LeerinkBoost TargetOutperform$42.00 ➝ $45.00Low
7/26/2022Piper SandlerBoost TargetOverweight$40.00 ➝ $41.00Low
7/14/2022Canaccord Genuity GroupReiterated RatingBuy$42.00Low
5/17/2022HC WainwrightBoost TargetBuy$45.00 ➝ $46.00N/A
5/6/2022Piper SandlerLower Target$42.00 ➝ $40.00High
3/30/2022Piper SandlerInitiated CoverageOverweight$42.00Medium
2/28/2022HC WainwrightInitiated CoverageBuy$45.00Medium
12/16/2021BarclaysBoost TargetOverweight$36.00 ➝ $40.00Medium
12/16/2021SVB LeerinkBoost TargetOutperform$37.00 ➝ $42.00Medium
8/17/2021SVB LeerinkBoost TargetOutperform$27.00 ➝ $37.00High
6/6/2021SVB LeerinkReiterated RatingBuyLow
5/26/2021SVB LeerinkBoost TargetOutperform$27.00 ➝ $35.00High
5/26/2021Evercore ISILower TargetOutperform$30.00 ➝ $23.00High
5/26/2021WedbushDowngradeOutperform ➝ Neutral$19.00High
5/26/2021BarclaysLower TargetOverweight$40.00 ➝ $34.00High
5/7/2021BMO Capital MarketsLower TargetOutperform$43.00 ➝ $38.00High
4/12/2021WedbushLower TargetOutperform$46.00 ➝ $39.00High
3/3/2021SVB LeerinkReiterated RatingOutperformHigh
3/2/2021BMO Capital MarketsLower Target$48.00 ➝ $43.00High
2/3/2021BMO Capital MarketsBoost TargetPositive ➝ Outperform$33.00 ➝ $48.00High
11/23/2020Evercore ISIInitiated CoverageOutperformMedium
(Data available from 5/28/2019 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/31/2023
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2023
  • 5 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/30/2023
  • 10 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2024
  • 9 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/28/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/29/2024
  • 7 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/28/2024
  • 9 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/28/2024

Current Sentiment

  • 9 very positive mentions
  • 17 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Travere Therapeutics logo
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $6.76
Low: $6.30
High: $7.02

50 Day Range

MA: $6.57
Low: $5.26
High: $8.09

52 Week Range

Now: $6.76
Low: $5.12
High: $19.54

Volume

1,323,413 shs

Average Volume

1,251,526 shs

Market Capitalization

$514.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Travere Therapeutics?

The following Wall Street analysts have issued reports on Travere Therapeutics in the last year: Bank of America Co., Barclays PLC, Canaccord Genuity Group Inc., Citigroup Inc., Evercore ISI, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Stifel Nicolaus, Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for TVTX.

What is the current price target for Travere Therapeutics?

12 Wall Street analysts have set twelve-month price targets for Travere Therapeutics in the last year. Their average twelve-month price target is $15.58, suggesting a possible upside of 130.5%. Bank of America Co. has the highest price target set, predicting TVTX will reach $27.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $9.00 for Travere Therapeutics in the next year.
View the latest price targets for TVTX.

What is the current consensus analyst rating for Travere Therapeutics?

Travere Therapeutics currently has 5 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TVTX.

What other companies compete with Travere Therapeutics?

How do I contact Travere Therapeutics' investor relations team?

Travere Therapeutics' physical mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The company's listed phone number is (888) 969-7879 and its investor relations email address is [email protected]. The official website for Travere Therapeutics is www.retrophin.com. Learn More about contacing Travere Therapeutics investor relations.